PERCEPTIVE INFORMATICS BOOSTS PERFORMANCE OF ITS eCLINICAL PLATFORM BY INCORPORATING BUSINESS INTELLIGENCE TECHNOLOGY
BOSTON, MA, November 18, 2010 — Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced that it has incorporated Information Builders’ WebFOCUS business intelligence technology into its enterprise reporting solution within its eClinical platform. This capability further enhances the performance of Perceptive’s eClinical platform, powered by industry-leading foundational technologies, including reporting, integration, and identity management solutions, which enable applications of its eClinical Suite.
Perceptive’s enterprise reporting solution within the eClinical platform is designed to provide rapid and efficient access to clinical study information and performance metrics. The WebFOCUS technology supports Perceptive’s enterprise reporting solution by providing expanded scalability and flexibility for eClinical applications that are designed to help biopharmaceutical companies securely monitor, analyze, and report study-related data.
“As clinical trials increase in complexity and scope, it is of paramount importance for biopharmaceutical companies to be able to more easily access and analyze data across applications in real-time to improve the performance of their development programs,” said Nicholas Richards, Vice President, Product Development, Perceptive Informatics. “Continued investment in our enterprise reporting infrastructure demonstrates our commitment to helping clients in making better, faster, and more informed decisions about their clinical trials. We are focused on changing the way data are accessed and used in clinical trials to streamline workflow and accelerate the clinical development process.”
The enterprise reporting component of Perceptive’s eClinical platform powers reporting functionalities within its eClinical Suite applications. The solution provides robust reporting for various trial management roles to assist in answering key questions through intelligent analysis and presentation of trial data. The reporting solution enables the monitoring of trial progress and performance, and provides dashboards with trending and forecasting functionalities, as well as customized searches for in-depth data analysis.
The eClinical Suite from Perceptive Informatics provides advanced integration and interoperability among systems, including the IMPACT® Clinical Trial Management System (CTMS), the DataLabs® EDC solution, and the ClinPhone® Randomization and Trial Supply Management (RTSM) technologies. The suite supports real-time data interchange and enables diverse applications to work synergistically. For more information about Perceptive’s eClinical Suite visit: http://www.perceptive.com/Solutions/eClinical-Suite.html.
About Information Builders
Information Builders’ award-winning combination of business intelligence and enterprise integration software has been providing innovative solutions to more than 12,000 customers for the past 30 years. WebFOCUS is the world’s most widely utilized business intelligence platform. It provides the security, scalability, and flexibility needed at every level of global extended enterprises. Its simplicity helps create executive, analytical, and operational applications that reach dozens to millions of users. Information Builders’ iWay Software suite provides state of the art, multi-purpose, pre-built integration components that address all SOA, application, data and information management requirements. Its integration adapters have been adopted by the leading software platform providers. Information Builders also offers solutions in the performance management, business activity monitoring, and enterprise search markets. The company’s comprehensive enterprise product offerings give Information Builders’ customers the ability to grow and innovate according to their needs. Information Builders’ customers include most of the Fortune 100 and U.S. federal government agencies. Headquartered in New York City with 90 offices worldwide, the company employs 1,450 people and has more than 350 business partners.
About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive’s eClinical Suite visit: www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 54 countries around the world, and has approximately 10,170 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 as filed with the SEC on November 9, 2010, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.